Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
RESULTS OF A RANDOMIZED PHASE-III TRIAL TO EVALUATE THE EFFICACY OF SR-89 ADJUVANT TO LOCAL FIELD EXTERNAL BEAM IRRADIATION IN THE MANAGEMENT OF ENDOCRINE RESISTANT METASTATIC PROSTATE-CANCER
Autore:
PORTER AT; MCEWAN AJB; POWE JE; REID R; MCGOWAN DG; LUKKA H; SATHYANARAYANA JR; YAKEMCHUK VN; THOMAS GM; ERLICH LE; CROOK J; GULENCHYN KY; HONG KE; WESOLOWSKI C; YARDLEY J;
Indirizzi:
WAYNE STATE UNIV,DEPT RADIAT ONCOL,3990 JOHN R DETROIT MI 48201 LONDON REG CANC INST LONDON ON CANADA CROSS CANC CTR EDMONTON AB CANADA TORONTO BAYVIEW CANC CTR TORONTO ON CANADA OTTAWA REG CANC CTR OTTAWA ON CANADA NEWFOUNDLAND CANC CLIN ST JOHNS NF CANADA AMERSHAM INT PLC AMERSHAM ENGLAND HAMILTON REG CANC CTR HAMILTON ON CANADA
Titolo Testata:
International journal of radiation oncology, biology, physics
fascicolo: 5, volume: 25, anno: 1993,
pagine: 805 - 813
SICI:
0360-3016(1993)25:5<805:ROARPT>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
SR-89 THERAPY; HEMIBODY IRRADIATION; OSSEOUS METASTASES; PAIN PALLIATION; BONE; CARCINOMA; RADIATION; P-32; HALF;
Keywords:
PROSTATE CANCER; RADIOTHERAPY; SR-89; OSSEOUS METASTASES;
Tipo documento:
Article
Natura:
Periodico
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
A.T. Porter et al., "RESULTS OF A RANDOMIZED PHASE-III TRIAL TO EVALUATE THE EFFICACY OF SR-89 ADJUVANT TO LOCAL FIELD EXTERNAL BEAM IRRADIATION IN THE MANAGEMENT OF ENDOCRINE RESISTANT METASTATIC PROSTATE-CANCER", International journal of radiation oncology, biology, physics, 25(5), 1993, pp. 805-813

Abstract

Purpose: A large proportion of the practice of radiotherapy in the management of metastatic adenocarcinoma of the prostate is associated with palliation of pain from osseous metastases and improving quality oflife. Radiation therapy is well known to be effective in treating painful sites and may also be effective in reducing the propensity for adjuvantly treated disease to become symptomatic. Strontium-89 is a systemic radionuclide that has clinical efficacy in the palliation of painfrom bony metastases. Methods and Materials: The study was a Phase-III randomized placebo control trial performed in eight Canadian Cancer Centers to evaluate the effectiveness of strontium-89 as an adjunct tolocal field radiotherapy. Patients with endocrine refractory metastatic prostate cancer received local field radiotherapy and either strontium-89 as a single injection of 10.8 mCi or placebo. Results: One hundred twenty-six patients were recruited. No significant differences in survival or in relief of pain at the index site where noted. Intake ofanalgesics over time demonstrated a significant reduction in the arm treated with strontium-89. Progression of pain as measured by sites ofnew pain or the requirement for radiotherapy showed statistically significant differences between the arms in favor of strontium-89. Tumor markers including prostate specific antigen, acid phosphatase, and alkaline phosphatase were also reduced in patients receiving strontium-89. A Quality-of-Life analysis was performed as a multivariate data set and demonstrated an overall superiority of strontium-89 with alleviation of pain and improvement in physical activity being statistically significant. Toxicity was evaluated and demonstrated increased hematological toxicity in the group receiving strontium-89. Conclusions: It is concluded that the addition of strontium-89 is an effective adjuvant therapy to local field radiotherapy reducing progression of disease as evidenced by new sites of pain and the requirement of further radiotherapy and improving quality-of-life and need for analgesic support in this group of patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/20 alle ore 01:05:57